The Lancet Rheumatology, 4(6), e417-e429. Lancet Publishing Group The Lancet. Rheumatology, 4, e417-e429 T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3 The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER The Lancet. Rheumatology, 4, 6, pp. e417-e429 The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd The Lancet Rheumatology, 4(6), e417-e429. Elsevier
The Lancet Rheumatology, 4(5), e338-e350. Elsevier The Lancet. Rheumatology, 4(5), e338-e350. Elsevier Ltd The Lancet Rheumatology, 4(5), E338-E350. ELSEVIER T2B! immunity against SARS-CoV-2 study group 2022, ' Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants : a cohort study ', The Lancet Rheumatology, vol. 4, no. 5, pp. e338-e350 . https://doi.org/10.1016/S2665-9913(22)00034-0 The Lancet Rheumatology, 4(5), e338-e350. Lancet Publishing Group The Lancet Rheumatology, 4(5), E338-E350. Lancet Publishing Group